Acalabrutinib (Calquence®). HTA ID: 23012

Assessment Status Rapid Review Complete
HTA ID 23012
Drug Acalabrutinib
Brand Calquence®
Indication Indicated as monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). The Applicant is seeking reimbursement in a subgroup of the licensed population: as monotherapy for previously untreated CLL without 17P deletion or TP53 mutation, in adult patients unsuitable for chemoimmunotherapy and venetoclax in combination with obinutuzumab.
Assessment Process
Rapid review commissioned 24/02/2023
Rapid review completed 31/03/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of acalabrutinib for this subgroup of the licensed population compared with the current standard of care.